Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
2026 · 2nd Quarter (Apr 1 - June 30)
GENENTECH, INC.
Filed by MARSHALL & POPP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 9, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- MARSHALL & POPP, LLC
- Client
- GENENTECH, INC.
- Filing UUID
- 509cc5ff-c135-43e7-8d3b-bf2efa485849
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
Issues related to tariff and trade policy.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.